Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Tern plc

Device Authority will use TechWorks Summit 2026 to strengthen its position in IoT and operational technology security, with a focus on continuous compliance, artificial intelligence and quantum risk.

The company will take part in the Secure track at the TechWorks Semiconductors to Systems Summit 2026. Chief Technology Officer James Penney is scheduled to speak on Continuous IoT & OT Compliance in the Age of AI and Quantum Risk.

The subject closely matches Device Authority’s core market. The company focuses on machine identity, connected-device security, automated credential management and post-quantum readiness. As more devices and operational systems become connected, businesses face a growing need to secure them continuously rather than rely on one-off controls.

TechWorks Summit 2026 brings together NMI, DESN, AESIN and the IoT Security Foundation for the first time. More than 600 industry leaders are expected to attend the 30th anniversary event, which is being delivered in partnership with the UK Semiconductor Centre.

Device Authority’s role in the Secure track is particularly relevant because cybersecurity is becoming more closely tied to the wider design and operation of connected systems. The company’s message is that compliance must be maintained throughout the lifecycle of IoT and OT assets, especially as AI introduces new security demands and quantum computing creates longer-term risks for existing encryption methods.

The summit also gives Device Authority a platform to position its technology around those changes before they become more pressing operational issues. Continuous compliance, automated machine identity and preparation for post-quantum security all sit within areas that organisations are increasingly having to address as connected infrastructure becomes more complex.

Senior commercial executives will also attend. Chief Executive Officer Darron Antill and Vice President of Sales EMEA Paul Lockley are due to join Penney at the event.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search